Key Highlights
- Net loss was USD 1,390,132 against USD 2,083,473 a year earlier, a decrease of USD 693,341, or 33%.
- The company reported no Revenue for the three months ended September 30, 2026 or the same period of 2025.
- Nine month net loss was USD 3,890,550 against USD 5,360,496, a decrease of USD 1,469,946, or 37%.
- Current Assets were USD 1.40 million against current liabilities of USD 7.19 million, and the filing includes Going Concern language.
ABVC BioPharma, Inc. (NASDAQ:ABVC) filed its Quarterly Report for the period ended September 30, 2026, on November 10, 2026. The filing shows a net loss of USD 1,390,132 for the three months, compared with USD 2,083,473 a year earlier. That is a decrease of USD 693,341, or 33%. The company reported no revenue in either period, and the source table carried no Earnings or revenue estimates for the quarter.
For the nine months ended September 30, 2026, net loss was USD 3,890,550 compared with USD 5,360,496 a year earlier, a decrease of USD 1,469,946, or 37%. Revenue was also zero for the nine month periods in both years.
Licensing Revenue and Shares Received
The filing states that, as of September 30, 2026, the company received 5 million shares of another company's stock but did not recognize licensing revenue for them. The filing explains that the Fair Value of that stock is uncertain. The company therefore reports no revenue for the period despite the arrangement described in the filing.
This is a point for readers who compare the filing with earlier periods, since the accounting treatment determines whether licensing consideration appears in the income statement. The accounting policy discussion in the filing is the primary source for how the company evaluates that consideration.
Liquidity and Going Concern
The Liquidity discussion shows current assets of USD 1,404,384 at September 30, 2026, compared with USD 3,261,343 at December 31, 2025, which the filing labels as revised. Current liabilities were USD 7,192,554, compared with USD 6,923,976 at year end. The result is a Working Capital deficit.
The filing states that the decrease in net cash provided by financing activities for the nine months was USD 3,267,206, primarily due to a repayment of short-term borrowings of about USD 0.7 million. The filing also states that conditions give rise to substantial doubt about the company's ability to continue as a going concern.
The filing reports accrued Research and Development expense of USD 1,741,083 at September 30, 2026, representing amounts due to third parties for outside contracted services for Manufacturing and process development. The filing states that management reviewed the stage of clinical trial activities during the nine months and found no significant changes in stage, no new vendors and no modifications to contracts.
Items to Follow
The Balance Sheet comparatives in the filing are labeled as revised, so the label applies to the year end figures. The company's quarterly report also describes subsidiaries and affiliated entities, and it references corporate transactions dated in August 2026. Those items appear in the filing's notes and are reported there.
The items to follow are the company's cash balance, financing activity, the treatment of the shares it received, and any change in the going concern language in future filings. The filing's legal proceedings and related party disclosures are reported there and flagged for human legal review.
Because no revenue was reported, the company's quarterly results are driven by operating expenses, research and development activity and financing costs. The decrease in net loss reflects the figures stated in the filing, and the filing is the primary source for the line item detail behind it.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...